Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives
V De Gaetano, M Pallozzi, L Cerrito, F Santopaolo… - Cancers, 2024 - mdpi.com
Simple Summary Portal hypertension (PH) and hepatocellular carcinoma (HCC) are major
complications of liver cirrhosis with a detrimental impact on patient outcomes that share …
complications of liver cirrhosis with a detrimental impact on patient outcomes that share …
Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation
M Li, S Bhoori, N Mehta, V Mazzaferro - Journal of Hepatology, 2024 - Elsevier
Immunotherapy has revolutionized treatment of advanced hepatocellular carcinoma (HCC).
In addition, several phase III trials of immunotherapy in early-to intermediate-stage HCC in …
In addition, several phase III trials of immunotherapy in early-to intermediate-stage HCC in …
Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian …
G Cabibbo, B Daniele, M Borzio… - Digestive and Liver …, 2024 - Elsevier
Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer-
related death. The remarkable improvements in treating HCC achieved in the last years …
related death. The remarkable improvements in treating HCC achieved in the last years …
[HTML][HTML] Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices
Randomized controlled trials (RCTs) represent the gold standard for evidence generation
across all areas of medicine and especially in the oncology field, as they allow unbiased …
across all areas of medicine and especially in the oncology field, as they allow unbiased …
[HTML][HTML] Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis
M Chen, Y Li, M Cheng - BMC gastroenterology, 2024 - Springer
Objective To evaluate the efficacy and safety of the combination of camrelizumab and
apatinib in the treatment of liver cancer and to furnish clinical recommendations for …
apatinib in the treatment of liver cancer and to furnish clinical recommendations for …
Reply to:“irLI or not irLI: That is the question”
In our observational, multicentre, international study, we did not formally evaluate causality
assessment tools, such as the Roussel Uclaf Causality Assessment Method (RUCAM). The …
assessment tools, such as the Roussel Uclaf Causality Assessment Method (RUCAM). The …
[引用][C] irLI or Not irLI: That is the Question
L Meunier, E De Martin, Y Horsmans… - Journal of …, 2024 - journal-of-hepatology.eu
We read with great interest the article by Celsa et al.(1) about the incidence, characteristics
and outcomes of immunotherapy-related liver injury (irLI) in patients with hepatocellular …
and outcomes of immunotherapy-related liver injury (irLI) in patients with hepatocellular …